Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xigris meeting rescheduled

Executive Summary

FDA's Anti-Infective Drugs Advisory Committee will consider Lilly's Xigris (drotrecogin alfa) BLA on Oct. 16 at the Hilton in Gaithersburg, Md. starting at 8:30 a.m. The original Sept. 12 meeting was rescheduled following the terrorist attacks on Washington, D.C. and New York City (1"The Pink Sheet" Sept. 17, pp. 10 & 212)

You may also be interested in...



Ochsner Clinic Xigris Budget Projected At $2 Mil. Per Year

The Ochsner Clinic Foundation estimates that its budget for Lilly's sepsis agent Xigris could be over $2 mil. per year.

Ochsner Clinic Xigris Budget Projected At $2 Mil. Per Year

The Ochsner Clinic Foundation estimates that its budget for Lilly's sepsis agent Xigris could be over $2 mil. per year.

FDA Xigris Efficacy Analysis Suggests APACHE II Test Can Guide Therapy

An FDA analysis of Lilly's Xigris Phase III efficacy data suggests that the APACHE II sepsis scale may be a useful guide for identifying candidates for therapy.

UsernamePublicRestriction

Register

OM013658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel